CAPTRUST Financial Advisors
PHAS

CAPTRUST Financial Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-521
Closed -$2K – 4860
2021
Q2 		$2K Buy
+521
New +$1.73K ﹤0.01% 4237

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

CAPTRUST Financial Advisors's PHAS Position: Q3 2021 in Review

CAPTRUST Financial Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2021, closing a stake of 521 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in PHAS in Q2 2021 and held it in 1 quarter. The position peaked at $2K in Q2 2021. 61 funds tracked by Wall St. Rank hold PHAS as of Q3 2021.

  • CAPTRUST Financial Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 521 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $2K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.